NewAmsterdam Pharma Company NAMS Foreign currency remeasurement (loss) gain on debt
Foreign currency remeasurement (loss) gain on debt at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's foreign currency remeasurement (loss) gain on debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's foreign currency remeasurement (loss) gain on debt?
- NewAmsterdam Pharma Company (NAMS) reported foreign currency remeasurement (loss) gain on debt of -$1.61M in Q1 2026.
- How has NewAmsterdam Pharma Company's foreign currency remeasurement (loss) gain on debt changed year-over-year?
- NewAmsterdam Pharma Company's foreign currency remeasurement (loss) gain on debt decreased by 137.6% year-over-year, from $4.29M to -$1.61M.
- What is the long-term trend for NewAmsterdam Pharma Company's foreign currency remeasurement (loss) gain on debt?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's foreign currency remeasurement (loss) gain on debt has grown at a 66.6% compound annual growth rate (CAGR), from $1.71M to $13.14M.
- What does foreign currency remeasurement (loss) gain on debt mean?
- This represents the net gain or loss resulting from fluctuations in exchange rates on transactions denominated in currencies other than the company's functional currency. It captures the impact of currency volatility on operational cash flows before tax considerations. Monitoring this helps investors assess the company's exposure to international market risks.